Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Benesch, M; Siegler, N; von Hoff, K; Lassay, L; Kropshofer, G; Müller, H; Sommer, C; Rutkowski, S; Fleischhack, G; Urban, C.
Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
Anticancer Drugs. 2009; 20(9): 794-799. Doi: 10.1097/CAD.0b013e32832f4abe
Web of Science PubMed FullText FullText_MUG Google Scholar

Leading authors Med Uni Graz: Benesch Martin; Urban Ernst-Christian
Co-authors Med Uni Graz: Sommer Constanze
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: This retrospective study aimed to evaluate the safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with refractory or recurrent brain tumors. Nineteen heavily pretreated patients (males, n = 14; females, n = 5; median age at diagnosis 8.5 years; range, 1.4-22 years) were given intrathecal liposomal cytarabine on a compassionate use basis for recurrent refractory medulloblastoma (n = 12), mixed germ cell tumor (n = 2), central nervous system primitive neuroectodermal tumors of the pons (n = 1), anaplastic ependymoma (n = 1), anaplastic oligodendroglioma (n = 1), atypical teratoid rhabdoid tumor (n = 1), or rhabdoid papillary meningioma (n = 1). Eighteen patients received concomitant systemic radiochemotherapy. A total of 88 intrathecal injections of liposomal cytarabine (dose range, 20-50 mg) were administered with concomitant dexamethasone prophylaxis. The median number of doses per patient was four (range, 1-10). Duration of treatment ranged from (1/2) to 10 months. Eleven patients (57.9%) did not show any side effects, whereas eight patients (42.1%) developed side effects related to either chemical arachnoiditis (n = 4) or neurological progression (n = 2). Less typical treatment-related symptoms (e.g. lethargy, ataxia, and slurred speech) were observed in two patients. Treatment with intrathecal liposomal cytarabine was discontinued twice because of side effects. In conclusion, although intrathecal liposomal cytarabine was generally well tolerated, it should be used cautiously and only with dexamethasone prophylaxis in extensively pretreated patients with recurrent brain tumors. Proof of efficacy requires a prospective single-agent phase II study.
Find related publications in this database (using NLM MeSH Indexing): Adolescent -; Antimetabolites, Antineoplastic - administration and dosage; Brain Neoplasms - diagnosis; Child -; Child, Preschool -; Cytarabine - administration and dosage; Delayed-Action Preparations -; Drug Resistance, Neoplasm -; Female -; Humans -; Infant -; Injections, Spinal -; Liposomes - administration and dosage; Male -; Retrospective Studies -; Salvage Therapy -; Young Adult -
Find related publications in this database (Keywords): brain tumors; children; intrathecal liposomal cytarabine; medulloblastoma; relapse